Glenmark's new generic gets FDA nod

Glenmark Pharmaceuticals receives ANDA approval for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg

id-10039602

The drug is the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals

Glenmark Pharmaceuticals(Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg. The drug is the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals (Bayer).

Glenmark plans to commence shipping of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg immediately.

According to IMS Health sales data for the 12 month period ending June 2015, the Yaz market achieved annual sales of approximately $170.1 million.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X